Backed by the federal government’s Economic Accelerator (AEA) Ignite Grant, the development by researchers from the University of South Australia (UniSA) promises to transform the way that gastrointestinal cancers are detected and treated with precise, minimally invasive surgery.
Led by Dr Nicole Dmochowska from UniSA’s Future Industries Institute, the $405,050 project is being undertaken in partnership with Ferronova.
The probe will work alongside Ferronova’s iron-oxide nanoparticle formulation (FerroTrace) to improve the detection of cancerous lymph nodes during surgery, reducing the need for extensive procedures that can lead to life-threatening complications and life-long side-effects for survivors.
Gastrointestinal cancers are among the deadliest, often spreading through the lymphatic system to distant lymph nodes before diagnosis. Traditional surgical methods involve removing large sections of tissue, increasing the risk of infections and long-term digestive issues.
MORE FROM MEDICAL & HEALTHCARE
“By integrating state-of-the-art quantum sensors into a minimally invasive laparoscopic probe, we aim to give surgeons a powerful new tool to precisely locate affected lymph nodes,” Dr Dmochowska said in a statement. “This will potentially enable more targeted surgery, reducing the need for extensive tissue removal and improving post-surgical recovery.”
The UniSA research team has demonstrated the feasibility of the quantum sensor-based magnetometer probes in a phase-1 clinical trial for oral cancer.
This new project will take this technology further by miniaturising the probe for use in laparoscopic (keyhole) surgery.
Researchers have spent over eight years developing the magnetometer probes for cancer surgery. The AEA Ignite grant will fund the development of a fully functional, preclinically validated prototype that can be trialled in large animal models before progressing to human clinical trials.
Unlike existing lymphatic mapping techniques that rely on radioactive tracers, the quantum probe and FerroTrace combination provide a safer and more effective combination, according to Ferronova senior researcher and development engineer Dr Aidan Cousins.
“This technology is particularly promising for patients undergoing chemotherapy and radiotherapy before surgery, where conventional lymphatic mapping methods have limited effectiveness,” said Dr Cousins. “This could be a paradigm shift in cancer treatment, enhancing the quality of life for millions of patients worldwide.”
Preclinical trials are expected to start within the next year.
Emergency law passed to protect UK steelmaking
<b>(:-))</b> Gareth Stace as director general of trade body UK Steel, is obviously an expert on blast furnace technology & operation. Gareth...